Table 1.

National Surgical Adjuvant Breast and Bowel Project B-24 results with 12-year follow-up

	L+XRT + placebo, N (%)	L+XRT + tamoxifen, N (%)
Ipsilateral breast tumor	149 (16.6)	119 (13.2)
Invasive	81 (9.0)	59 (6.6)
Noninvasive	68 (7.6)	60 (6.7)
Contralateral breast tumor	73 (8.1)	44 (4.9)
Invasive	48 (5.3)	30 (3.3)
Noninvasive	25 (2.8)	14 (1.6)
Other local, regional, or distant recurrence	10 (1.1)	7 (0.8)
Second cancer, except opposite breast	64 (7.1)	71 (7.9)
Dead, NED	49 (5.4)	48 (5.3)
Total first events	345 (38.3)	289 (32.1)
Alive, event-free	555 (61.7)	610 (67.9)
Total patients	900 (100.0)	899 (100.0)

^*L+XRT= lumpectomy and radiation therapy; NED = no evidence of disease.